Price T Rowe Associates Inc Actinium Pharmaceuticals, Inc. Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 12,785 shares of ATNM stock, worth $23,268. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,785Holding current value
$23,268% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ATNM
# of Institutions
72Shares Held
8.18MCall Options Held
51.9KPut Options Held
6.2K-
Black Rock Inc. New York, NY1.88MShares$3.41 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.57MShares$2.86 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA712KShares$1.3 Million0.0% of portfolio
-
State Street Corp Boston, MA645KShares$1.17 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA504KShares$917,3490.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $45.8M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...